Board of Directors

Mr. Matricaria was appointed to the Board in March 2014. He has more than 35 years of medical device and pharmaceutical experience at St. Jude Medical, Inc. (now Abbott) and Eli Lilly and Company, Inc. From April 1993 to May 1999, Mr. Matricaria served as President and Chief Executive Officer of St. Jude Medical, Inc. and served as Chairman of the Board of Directors from January 1995 to May 2002. Prior to joining St. Jude Medical, he spent 23 years with Eli Lilly and Company, Inc., where his last position was Executive Vice President of the Pharmaceutical Division of Eli Lilly and Company and President of its North American operations. Mr. Matricaria also served as President of Eli Lilly International Corporation, as well as President of its Medical Device Division. He previously served as a director of Kinaxis Inc. a SaaS based software company traded on the Toronto Stock Exchange, as Chairman of the Board at Volcano Corporation and as a member of the Boards of Phoenix Children’s Hospital and Life Technologies Corporation. Additionally, he previously served on a number of other public and private companies boards including Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association (AdvaMed), the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center and the Indiana Repertory Theatre as well as a trustee on the board of the Massachusetts College of Pharmacy and Allied Health Science. Mr. Matricaria also chaired the BioMedical Engineering Institute campaign, which raised an operating endowment for the Institute at the University of Minnesota. He remains a Trustee emeritus of the University of Minnesota Foundation. Mr. Matricaria holds a bachelor’s degree in pharmacy from the Massachusetts College of Pharmacy, as well as an honorary PharmD degree, in recognition of his contributions to the practice of pharmacy.

Mr. Hannon joined the Orthofix Board of Directors in June 2020. A seasoned medical device executive, he currently serves as the President and Chief Executive Officer of Mainstay Medical International plc, a global company headquartered in Ireland that is focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions. Mr. Hannon has also served as President and Chief Operating Officer of NuVasive, Inc. Over the course of 12 years at NuVasive, he held various roles of increasing responsibility, including as Executive Vice President, International; and Executive Vice President, Corporate Development; and General Counsel. Mr. Hannon also serves as a director on the board of Sequana Medical NV, a publicly traded medical device company focused on the development of innovative treatment options for the management of fluid overload in liver disease, malignant ascites and heart failure. Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.

Mr. Hinrichs was appointed to the Board in April 2014. From 2018 to 2019, he served as Chief Financial Officer of Cibus, a privately-held agricultural biotech company. Prior to this, Mr. Hinrichs served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company, preceding its sale to Abbott Labs. From December 2010 through March 2015, he served as Chief Financial Officer of CareFusion Corporation, prior to its sale to Becton Dickinson. Mr. Hinrichs previously served as CareFusion's Senior Vice President, Global Customer Support, and as its Senior Vice President, Controller. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following more than a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University. Mr. Hinrichs serves as a director of Integer Holdings Corporation, Acutus Medical Inc., and Outset Medical. He also serves as a director of Signifier Medical Technologies, a privately-held company.

Mr. Lukianov joined the Board in December 2016, bringing more than 30 years of experience in the orthopedic industry. He is Chairman and CEO of Tissue Differentiation Intelligence, LLC, a privately-held ultrasound spine company formed in 2017, and is Chairman and CEO of DuraStat, LLC, a privately-held surgical device company formed in 2017. He previously served as Chief Executive Officer and a director of NuVasive, Inc., where he served as Chairman of their Board from 2004 to 2015. Mr. Lukianov was a founder of and served as Chairman of the Board and CEO of BackCare Group, Inc. Prior to this, he held a variety of senior executive positions, including President, with Medtronic Sofamor Danek, Inc., and director of a business unit at Smith & Nephew Orthopaedics, that brought limb lengthening technology to the United States from Russia. Mr. Lukianov has previously served on the Board of Directors of Volcano Corporation, a Nasdaq-listed medical technology company, and on the boards and the executive committees of BIOCOM, a regional life sciences trade association, the Medical Device Manufacturers Association (MDMA), a national trade association, and the California Health Institute (CHI). Mr. Lukianov also serves on a number of private and non-profit boards.

Ms. Marks joined the Board in June 2015. She currently serves as the Vice President for Health Affairs for the University of Colorado and Anschutz Medical Campus, which includes the university’s Schools of Medicine, Dental Medicine, Pharmacy, Public Health, College of Nursing and Graduate School and the University of Colorado Hospital and Children’s Hospital Colorado. Prior to her health campus leadership role, Ms. Marks spent two decades as both Senior Associate Dean for Finance and Administration at the School Of Medicine and Executive Director of University Physicians, Inc., the 501(c)(3) faculty practice plan. She has served as Chair of the Board of Directors of the University of Colorado Hospital and is a board member of the Board of Directors of the Federal Reserve Bank of Kansas City, the Fitzsimons Redevelopment Authority, the Association of Academic Health Centers (AAHC), the Global Down Syndrome Foundation, and the Rose Community Foundation. She was formerly the chair of the board of the Association of American Medical Colleges (AAMC) and is currently a member of the AAMC Advisory Panel on Research and a trustee of the University of Colorado Foundation. Ms. Marks is a graduate of the University of Colorado.

Mr. Paolucci was named to the Board of Directors and appointed to the Compensation Committee in March 2016. A seasoned Human Resource (HR) executive, he has more than 20 years of global experience working directly with Boards of Directors and C-level executives to improve organizational capabilities and HR programs that result in sustained improvements in business performance. From 2015 until 2020, Mr. Paolucci served as Vice President and Chief Human Resources Officer for Halozyme Therapeutics Inc., a late stage oncology and biopharmaceutical company. Prior to Halozyme, he served as Executive Vice President and Chief Human Resource Officer for CareFusion. Mr. Paolucci also served as Executive Vice President of Human Resources at NuVasive, and spent five years at Life Technologies. Previously, he was head of Human Resources for the services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, Mr. Paolucci was a partner with the HR consulting firm Towers Perrin. Mr. Paolucci is a graduate of Ohio State University.

Ms. Sainz became a director of Orthofix in November 2012, after previously having served on the Board from June 2008 to September 2011. Currently, she is the President and CEO of AEGEA Medical, Inc., a privately-held women’s health company in the field of endometrial ablation. Previously, Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a heart failure related medical device company. Prior to this, she was the President and Chief Executive Officer of Concentric Medical, Inc. up to and during its acquisition by Stryker Corporation in October 2011. Upon this acquisition, Ms. Sainz served as General Manager of the Stryker Neurovascular business unit. From 2003 to 2006, she was the President of the Cardiac Surgery division of Guidant Corporation. After Boston Scientific acquired Guidant, Ms. Sainz led the integration process for both the Cardiac Surgery and European Cardiac Rhythm Management business of Guidant into Boston Scientific. Between 2001 and 2003, she was the Vice President of Global Marketing – Vascular Intervention of Guidant. Ms. Sainz earned a Bachelor and Masters of Arts from the Universidad Complutense de Madrid and a Master’s Degree in International Management from American Graduate School of International Management. She has served as a director of Avanos Medical, Inc. (formerly Halyard Health, Inc.) since 2015, and Shockwave Medical Inc. since 2020. Ms. Sainz also serves as a director of Levita Magnetics and Artio Medical, both of which are privately-held companies. Ms. Sainz previously served as a director of Iridex Corporation from 2018 to 2020, the Spectranetics Corporation from 2010 until its sale in August 2017, and of MRI Interventions, Inc. from 2014 to 2018.

Mr. Serbousek joined Orthofix in August 2019 and became director, President and CEO in November 2019. A seasoned executive with more than 30 years’ experience in the medical device and biotech industries, Mr. Serbousek served in several leadership positions at Biomet Inc., including Worldwide President of Biomet Biologics, Worldwide Group President of Orthopedics, and President of U.S. Orthopedics. Prior to joining Biomet, he held various general management positions within Medtronic Inc., including Worldwide Division President − Spine, and Worldwide Vice President and General Manager of Biologics for their Spine and Biologics business. Additionally, Mr. Serbousek spent 13 years with DePuy Orthopedics, a Johnson & Johnson company where he served in numerous roles of increasing responsibility, including Vice President of Marketing and Product Development and Vice President of Spinal Operations. Mr. Serbousek has held numerous board positions at for profit and not-for-profit organizations. He earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah, and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.

Mr. Sicard joined the Board in March 2018. He currently serves as the President and Chief Executive Officer, and a Board Member of Kinaxis, a global supply chain management software company that delivers cloud-based solutions to some of the world’s largest manufacturing companies, including many in the life science sector. Mr. Sicard joined Kinaxis in 1994 where he has held a number of senior management roles including Chief Product Officer, Chief Strategy Officer, Chief Operating Officer, Executive Vice President of Marketing Development and Service Operations and Vice President of Professional Services. Prior to Kinaxis, Mr. Sicard held positions at FastMAN Software Systems, and Monenco Agra. Mr. Sicard is a graduate of Concordia University, Montreal, Canada, and the Harvard Business School Advanced Management Program.